Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines

53Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

New malaria vaccines are urgently needed to improve vaccine protective efficacy. PfCelTOS is a recombinant malaria vaccine antigen that has shown protective efficacy in a small-animal challenge model when combined with a water-in-oil emulsion adjuvant (Montanide ISA 720). In this report, we show that PfCelTOS vaccines containing GLA-SE (a stable oil-in-water emulsion combined with a Toll-like receptor 4 [TLR4] agonist) elicit strong Th1-type immune responses in BALB/c mice. These responses include higher antigen-specific IgG2a antibody titers and more gamma interferon (IFN-γ) production than those seen with a PfCelTOS vaccine containing Montanide ISA 720. Furthermore, reducing the emulsion dose from 2% to 1% or 0.5% (vol/vol) squalene in GLA-SE did not compromise immunogenicity. Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Fox, C. B., Baldwin, S. L., Vedvick, T. S., Angov, E., & Reed, S. G. (2012). Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clinical and Vaccine Immunology, 19(10), 1633–1640. https://doi.org/10.1128/CVI.00235-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free